Chemicalinfo Chemlink Pharm-Chem Net

多靶点抗肿瘤酪氨酸激酶抑制剂 中国医学科学院肿瘤医院     孙燕 王燕 周爱萍 李勇     近年来,随着分子生物学技术的进展和从细胞受体与增殖调控的分子水平对肿瘤发病机制认识的进一步深入,针对细胞受体、关键基因和调...

Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla® (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries

Cancer News Article ord=Math.random()*10000000000000000;document.write('');Sprycel® Effective for CNS Philadelphia Chromosome-...

Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma Donna E. Reece,* Giovanni Piza Rodriguez, Christine Chen, Suzanne Trudel, Vishal Kukreti, Joseph Mikhael, Mariela Pantoja, Wei Xu, an...

Cipla eyeing copies of 20 patented drugsDrug maker obtains similar-sounding trademarks for copycat versions of at least five global drug giantsMumbai: Cipla Ltd, India’s second largest drug maker by sales, may launch copycat versions of 20 pate...

Cyclacel Publishes Study of Seliciclib Synergy with Tarceva(Erlotinib) and Herceptin in Journal Clinical Cancer Research -- Increased Antitumor Activity and Molecular Mechanism Explored -- BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuti...

FDA MedWatch- Avastin (bevacizumab) and Sunitinib Malate- Reports of Microangiopathic Hemolytic Anemia In Patients Treated With This Combination ROCKVILLE, Md., July 14, 2008--Genentech, Inc. informed healthcare professionals of reports of sever...

最近美国临床药理和治疗学协会一个研究表明：在进食中服用，而不是空腹条件下，服用昂贵的治疗乳腺癌药物-拉帕替尼(Lapatinib)，能提高机体对药物吸收，降低治疗所需的药物剂量，能为患者大大减少治疗费用。在进食时服用500毫克的拉帕替尼能得到与空腹时服用1250毫克的拉帕替尼相同的治疗效果。

Infinity Pharmaceuticals Named as One of the Best Places to WorkInfinity's President of Research and Development Julian Adams, Ph.D. Named as One of the Most Influential People in Life Sciences Last update: 8:33 a.m. EDT July 9, 2008CAMBRIDGE, Mass.,...

Indian Patent office to hear drug firms` views before granting licence The Indian patent office will provide drug innovators a chance to explain their views before a decision to grant compulsory licences against their patented medicines is taken. The...